HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ray, W A Articles by Griffin, M R Search for Related Content PubMed PubMed Citation Articles by Ray, W A Articles by Griffin, M R

Lipid-lowering agents and the risk of hip fracture in a Medicaid population

¹ Department of Preventive Medicine, Vanderbilt University School of Medicine and the Geriatric Research, Education and Clinical Center, Nashville VAMC, Nashville, Tennessee, USA
² Department of Preventive Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
³ Department of Preventive Medicine and the Department of Medicine, Vanderbilt University School of Medicine and the Geriatric Research, Education and Clinical Center, Nashville VAMC, Nashville, Tennessee, USA

Correspondence and reprint requests to:
Dr Wayne Ray, Department of Preventive Medicine, Medical Center North, A-1124, Vanderbilt University Medical Center, Nashville, TN 37232, USA;
wayne.ray{at}mcmail.vanderbilt.edu

Context: Three recent nested case-control studies conducted in automated databases suggest that users of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have a risk of hip and other osteoporotic fractures half that of non-users of any lipid-lowering drug. However, this comparison may be biased by unmeasured factors associated with treated hyperlipidemias.

Objective: To compare the risk of hip fracture among users of statins and other lipid-lowering agents, which is less susceptible to bias than the comparisons performed in the previous studies.

Design and setting: Retrospective cohort study conducted in the Tennessee Medicaid program between 1 January 1989 through 31 December 1998.

Subjects: New users of all lipid-lowering drugs and randomly selected non-user controls who at baseline were at least 50 years of age and did not have life threatening illness, nursing home residence, or diagnosed dementia or osteoporosis. There were 12 506 persons with new use of statins, 4798 with new use of other lipid lowering drugs, and 17 280 non-user controls.

Main outcome measure: Fracture of the proximal femur (hip), excluding pathological fractures or those resulting from severe trauma.

Results: During 66 690 person years of follow up, there were 186 hip fractures (2.8 per 1000). Relative to non-users, the adjusted incidence rate ratios (95% confidence interval) were 0.62 (0.45 to 0.85) for statin users and 0.44 (0.26 to 0.95) for other lipid-lowering drugs. When compared directly with the other drugs, the adjusted incidence rate ratio for statins was 1.42 (0.83–2.43).

Conclusion: These data provide evidence that the previously observed protective effect of statins may be explained by unmeasured confounding factors.

Keywords: lipid lowering agents; hip fracture

This article has been cited by other articles:

				H. G. Bone, D. P. Kiel, R. S. Lindsay, E. M. Lewiecki, M. A. Bolognese, E. T. Leary, W. Lowe, and M. R. McClung Effects of Atorvastatin on Bone in Postmenopausal Women with Dyslipidemia: A Double-Blind, Placebo-Controlled, Dose-Ranging Trial J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4671 - 4677. [Abstract] [Full Text] [PDF]

				M. A. Brookhart, A. R. Patrick, C. Dormuth, J. Avorn, W. Shrank, S. M. Cadarette, and D. H. Solomon Adherence to Lipid-lowering Therapy and the Use of Preventive Health Services: An Investigation of the Healthy User Effect Am. J. Epidemiol., August 1, 2007; 166(3): 348 - 354. [Abstract] [Full Text] [PDF]

				F. de Vries, C. de Vries, C. Cooper, B. Leufkens, and T.-P. van Staa Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int. J. Epidemiol., October 1, 2006; 35(5): 1301 - 1308. [Abstract] [Full Text] [PDF]

				W. A. Ray Evaluating Medication Effects Outside of Clinical Trials: New-User Designs Am. J. Epidemiol., November 1, 2003; 158(9): 915 - 920. [Abstract] [Full Text] [PDF]

				Minerva BMJ, October 6, 2003; 327(7418): E194 - 194. [Full Text] [PDF]

				Minerva BMJ, December 14, 2002; 325(7377): 1430 - 1430. [Full Text] [PDF]